Search Within

David Hyman

  1. "Qin Zhou"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (4)
Groups
  1. Biostatistics Service (13)
  2. Department of Medicine (13)
  3. Early Drug Development Service (13)
  4. Epidemiology and Biostatistics (13)
  5. Solid Tumor Oncology Division (13)
  6. GDMT, Medicine (12)

More Groups

People
  1. Alexia Iasonos (13)
  2. Qin Zhou (13)
  3. Rachel Grisham (11)
  4. Carol Aghajanian (10)
  5. David Spriggs (8)
  6. Gopakumar Iyer (5)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (1)
  5. 2015 (1)
  6. 2014 (2)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Gynecologic Oncology (3)
  3. Cancer (2)
  4. International Journal of Gynecological Cancer (2)
  5. Annals of Oncology (1)
  6. Cancer Discovery (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier B.V. (3)
  3. Lippincott Williams & Wilkins (2)
  4. Wiley Blackwell (2)
  5. American Association for Cancer Research (1)
  6. Oxford University Press (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics and outcome of AKT1(E17K)-mutant breast cancer defined through AACR Project GENIE, a clinicogenomic registry
    Journal Article

    Smyth, L. M.; Zhou, Q.; Nguyen, B.; Yu, C.; Lepisto, E. M.; Arnedos, M.; Hasset, M. J.; Lenoue-Newton, M. L.; Blauvelt, N.; Dogan, S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • The role of systemic chemotherapy in the management of granulosa cell tumors
    Journal Article

    Meisel, J. L.; Hyman, D. M.; Jotwani, A.; Zhou, Q.; Abu-Rustum, N. R.; Iasonos, A.; Pike, M. C.; Aghajanian, C.
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
    Journal Article

    Meisel, J. L.; Hyman, D. M.; Garg, K.; Zhou, Q.; Dao, F.; Bisogna, M.; Gao, J.; Schultz, N. D.; Grisham, R. N.; Phillips, M.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Garg, K.; DeLair, D.; Hyman, D. M.; Zhou, Q.; Iasonos, A.; Berger, M. F.; Dao, F.; Spriggs, D. R.; more...
    Cancer (2013)

    Fulltext@MSK | Save
  • A comprehensive analysis of BRAF and KRAS mutation status in low-grade serous (LGS) and serous borderline (SB) ovarian cancer (OC)
    Meeting Abstract

    Grisham, R. N.; Garg, K.; Zhou, Q.; Iasonos, A.; Berger, M. F.; Dao, F.; Hyman, D. M.; Levine, D. A.; Solit, D. B.; Aghajanian, C.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save